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Abstract
Background:  In  recent  years,  several  publications  have  shown  that  new  adhesives  and  sealants,
like Tissucol®,  applied  in  thyroid  space  reduce  local  complications  after  thyroidectomies.
Study aims:  To  demonstrate  the  effectiveness  of  ﬁbrin  glue  Tissucol® in  reducing  the  post-
operative hospital  stay  of  patients  operated  on  for  differentiated  thyroid  carcinoma  in  which
total thyroidectomy  with  central  and  unilateral  node  neck  dissection  was  performed  (due  to
the debit  drains  decrease),  with  consequent  cost  savings.
Material  and  methods:  A  prospective  randomised  study  was  conducted  during  the  period
between  May  2009  and  October  2013  on  patients  with  differentiated  thyroid  carcinoma  with
cervical nodal  metastases,  and  subjected  to  elective  surgery.  Two  groups  were  formed:  one
in which  Tissucol® was  used  (case  group)  and  another  where  it  was  not  used  (control  group).
Patients were  operated  on  by  surgeons  speciﬁcally  dedicated  to  endocrine  surgical  pathology,
using the  same  surgical  technique  in  all  cases.
Results:  A  total  of  60  total  thyroidectomies  with  lymph  node  dissection  were  performed,  with
30 patients  in  the  case  group,  and  30  patients  in  control  group.  No  statistically  signiﬁcant
differences  were  observed  in  most  of  the  studied  variables.  However,  the  case  group  had  a
shorter hospital  stay  than  the  control  group  with  a  statistically  signiﬁcant  difference  (p  <  0.05). Please cite this article as: Vidal-Pérez O, Flores-Siguenza L, Valentini M, Astudillo-Pombo E, Fernández-Cruz L, García-Valdecasas JC.
plicación de sellante de ﬁbrina en pacientes operados por cáncer diferenciado de tiroides. ¿Qué mejoramos?. Cir Cir. 2016;84:282--287.
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Conclusion:  Implementation  of  Tissucol® has  statistically  and  signiﬁcantly  reduced  the  hospi-
tal stay  of  patients  undergoing  total  thyroidectomy  with  neck  dissection,  which  represents  a
signiﬁcant  reduction  in  hospital  costs.  This  decrease  in  hospital  stay  has  no  inﬂuence  on  the
occurrence  of  major  complications  related  to  the  intervention.
© 2015  Academia  Mexicana  de  Cirug´ıa  A.C.  Published  by  Masson  Doyma  Me´xico  S.A.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
PALABRAS  CLAVE
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ganglionar
Aplicación  de  sellante  de  ﬁbrina  en  pacientes  operados  por  cáncer  diferenciado  de
tiroides.  ¿Qué  mejoramos?
Resumen
Antecedentes:  En  los  últimos  an˜os  han  aparecido  diferentes  publicaciones  que  demuestran  que
los nuevos  sellantes  adhesivos,  como  Tissucol®,  que  son  aplicados  en  el  espacio  tiroideo  reducen
las complicaciones  locales  tras  tiroidectomías  complejas.
Objetivos:  Mostrar  la  eﬁcacia  del  adhesivo  de  ﬁbrina  Tissucol® en  la  reducción  de  la  estancia
hospitalaria  postoperatoria  de  los  pacientes  intervenidos  de  carcinoma  diferenciado  de  tiroides
en quienes  se  realizó  tiroidectomía  total  con  vaciamiento  ganglionar  central  y  unilateral.
Material y  métodos:  Realizamos  un  estudio  prospectivo  y  aleatorizado,  durante  el  periodo  com-
prendido entre  mayo  de  2009  y  octubre  de  2013,  en  pacientes  con  carcinoma  diferenciado  de
tiroides con  metástasis  ganglionares  cervicales,  para  la  realización  de  cirugía  programada.  Se
formaron 2  grupos:  en  los  que  se  utilizó  Tissucol® (grupo  caso)  y  en  los  que  no  (grupo  control).
Los pacientes  fueron  operados  por  cirujanos  especialmente  dedicados  a  patología  quirúrgica
endocrina,  utilizando  la  misma  técnica  en  todos  ellos.
Resultados:  Realizamos  60  tiroidectomías  totales  con  vaciamiento  ganglionar:  30  en  el  grupo
caso, que  se  compararon  con  30  del  grupo  control.  No  observamos  diferencias  signiﬁcativas
en la  mayoría  de  las  variables  estudiadas;  no  obstante,  el  grupo  caso  presentó  una  menor
estancia hospitalaria  respecto  al  grupo  control,  con  una  diferencia  estadísticamente  signiﬁca-
tiva (p  <  0.05).
Conclusión:  La  aplicación  del  Tissucol® ha  permitido  reducir  la  estancia  hospitalaria  de  los
pacientes  operados  de  tiroidectomía  total  con  vaciamiento  cervical,  lo  que  representa  para
el hospital  una  reducción  de  costos,  sin  que  ello  inﬂuya  en  la  aparición  de  complicaciones
relacionadas  con  la  intervención.
©  2015  Academia  Mexicana  de  Cirug´ıa  A.C.  Publicado  por  Masson  Doyma  Me´xico  S.A.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The  incidence  of  differentiated  thyroid  cancer  is  increas-
ing  worldwide  (0.3--8.1  new  cases/100,000  inhabitants  per
year),  and  represents  90%  of  endocrine  tumours.1--4 As
we  know,  the  initial  therapeutic  approach  for  differenti-
ated  thyroid  cancer  is  total  thyroidectomy.5--8 In  the  case
of  advanced  papillary  carcinoma,  the  American  Thyroid
Association  (ATA)  also  recommends  performing  a  prophy-
lactic  lymphadenectomy  of  the  central  compartment  of  the
neck,7,9,10 as  this  is  the  ﬁrst  step  of  lymphatic  drainage  and,
if  necessary,  therapeutic  lymphadenectomy  of  the  lateral
cervical  compartment.  Therefore  it  is  important  to  mention
that  the  thyroid  is  in  a  site  where  complications  can  present
as  feared  as  recurrent  lesion,  deﬁnitive  hypoparathyroidism
and,  of  course,  haemorrhage,  asphyxiating  haematoma  and
seroma.  With  regard  to  these  latter  events,  some  surgeons
advocate  systematically  placing  drains  in  the  wound.11 How-
ever,  there  are  arguments  against  the  use  of  drains,  as  they
p
f
t
eften  become  blocked  with  coagulated  blood,  and  even
hen  they  are  in  place  collections  of  blood  or  tissue  ﬂuid
an  form.12--15 Furthermore,  placing  drains  implies  a  more
engthy  hospital  stay  and  can  even  increase  the  likelihood  of
nfection  and  pain.15,16 In  recent  years  various  publications
ave  demonstrated  that  the  new  haemostatic  agents  and
dhesive  sealants  (which  include  Tissucol  Duo®)  can  reduce
ocal  complications  after  thyroidectomy  and  hemithyroidec-
omy  when  applied  in  the  thyroid  space,17--28 associated
ith  decreased  drainage  debit  and  reduction  of  dead  space.
ibrin  adhesives  such  as  Tissucol  Duo® also  promote  wound
ealing,  stimulating  the  microphages  and  ﬁbroblasts,  thus
romoting  homeostasis  and  angiogenesis.21
The  main  objective  of  this  work  was  to  demonstrate
he  efﬁcacy  of  the  Tissucol® ﬁbrin  glue  in  reducing  the
ostoperative  hospital  stay  of  patients  operated  for  dif-
erentiated  thyroid  carcinoma  who  have  undergone  total
hyroidectomy  with  central  and  unilateral  lymph  node
mptying.
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Our  secondary  objective  was  to  demonstrate  a  reduction
n  local  complications.
aterial and methods
 prospective,  randomised  study  was  performed,  of  cases
nd  controls,  of  adult  patients  referred  to  the  General  and
ndocrine  Unit  of  Barcelona’s  Hospital  Clínic  with  a  diagno-
is  of  differentiated  thyroid  carcinoma  with  cervical  lymph
ode  metastases,  for  total  thyroidectomy  with  central  and
nilateral  lymph  node  emptying.  The  study  was  performed
etween  4  May  2009  and  31  October  2013.
The  diagnosis  of  differentiated  thyroid  carcinoma  was
ased  on  each  patient’s  history  and  clinical  examination,
ith  complementary  examinations  using  laboratory  studies,
hest  X-ray  and  cervical  ultrasound.
The  criteria  for  inclusion  in  the  study  were:  no  medi-
al  anaesthesia  contraindications  (ASA),  body  mass  index
BMI)  <  30,  with  no  contraindications  for  Tissucol  Duo® ﬁbrin
dhesives.
All  the  patients  were  operated  by  the  same  team:  2
urgeons  specialists  in  cervical  endocrine  disorders  with
xperience  of  more  than  1000  cases.  Demographic  variables
ere  collected  (age,  sex,  BMI)  and  the  clinical  characteris-
ics  of  the  patients  (date  of  admission,  date  of  discharge,
urgery  time,  length  of  incision,  the  anatomopathological
ype  of  the  tumour,  intraoperative  complications,  wound
aematoma,  seroma,  postoperative  pain  (visual  analogue
cale  0--10),  hypocalcaemia  (serum  calcium  <  8  mg/dl)  tran-
ient  dysphonia  and  hospital  stay)  following  the  Clinical
uidelines  for  Endocrine  Surgery  of  the  Spanish  Association
f  Surgeons,  and  the  average  cost  of  hospital  stay  per  day
in  euros).
A  total  of  60  consecutive  patients  were  included  in  the
tudy  who  had  undergone  total  thyroidectomy  with  central
nd  unilateral  lymph  node  emptying.
The  sample  size  of  each  group  was  calculated  based
n  the  criteria  for  comparison  of  means  in  a  signiﬁcance
est,  with  safety  level  (0.05),  power  of  the  trial  (95%),  vari-
nce  of  the  quantitative  variable  of  the  control  group  (4.35
ccording  to  previous  references),14 minimum  value  of  the
ifference  to  be  detected.
Randomisation  was  by  numbered  sealed  envelopes  which
ere  opened  just  before  the  incision  was  closed  and
he  Tissucol® ﬁbrin  glue  applied  to  the  patients  in  the
ase  group.  Postoperative  follow-up  was  blind  for  the
valuators.
Tissucol® ﬁbrin  glue  (Baxter,  Hyland  Inmuno  Reg.  No.:
0426  and  60427  of  the  Spanish  Medicines  Agency.  Kit  used
or  wounds  in  general)  was  used  in  the  case  group  without
praying  over  the  surgical  bed  (Baxter,  Hyland  Inmuno).
The  study  was  evaluated  and  tested  by  the  Research
ommittee,  the  Ethical  Committee  and  the  Management  of
he  Surgical  Ward  of  our  institution.  The  patients  received
nformed  consent  forms  which  were  signed  at  the  visit  to  the
linic,  prior  to  being  entered  on  the  waiting  list  for  surgery.
ll  the  patients  were  informed  of  the  possibility  of  other
herapeutic  options.
Once  the  information  had  been  gathered,  a  descriptive
nalysis  of  the  variables  was  made  (mean,  median,  standard
eviation).
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The  same  surgical  technique  and  the  same  preoperative
rotocol  were  used  in  all  the  patients.
Pain  was  controlled  with  the  usual  analgesic  regimen
paracetamol  +  Enantyum® alternated  every  8  h).
urgical  technique
he  surgeon  stood  on  the  right  side  of  the  patient  with  their
ssistant  opposite.  A  transversal  cervical  incision  was  made
 cm  from  the  sternal  notch,  from  5  cm  to  8  cm  long  (depend-
ng  on  whether  or  not  central,  latero-cervical  lymph  node
mptying  was  required).  The  external  limits  were  marked
y  the  posterior  edge  of  the  sternocleidomastoid  muscle
Fig.  1).  Then  the  planes  were  opened  with  the  creation  of
pper  and  lower  myocutaneous  ﬂaps,  section  of  the  midline
f  the  deep  cervical  fascia  and  separation  of  the  infrahyoid
usculature,  to  expose  both  thyroid  lobes,  with  systematic
artial  section  of  the  sternothyroid  muscle  at  the  level  of  its
nsertion  into  the  thyroid  cartilage.  Then  the  upper  pedicle
as  sealed  and  sectioned,  close  to  the  thyroid  surface,  to
revent  injury  to  the  external  branch  of  the  upper  laryngeal
erve.  The  parathyroid  glands  were  identiﬁed  and  pre-
erved.  The  recurrent  laryngeal  nerve  was  identiﬁed  below
ts  intersection  with  the  lower  thyroid  artery.  Resection  of
he  corresponding  lobule  was  completed,  separating  it  from
he  traquea,  and  the  same  manoeuvres  performed  on  the
ontralateral  lobule  until  the  total  thyroidectomy  was  com-
leted.
When  the  thyroidectomy  was  completed,  we  performed
entral,  bilateral  lymph  node  emptying  of  the  neck  or  level
i  and  we  associated  functional  therapeutic  laterocervical
ymph  node  emptying  or  levels  IIA--IIB--III--IV  on  the  side
f  the  tumour,  as  described  in  the  guidelines  of  the  Span-
sh  Association  of  Surgeons,  after  conﬁrming  the  presence
f  pathological  lymph  nodes  by  ultrasound  and/or  ﬁnding
hem  intraoperatively  (Fig.  2).  The  entire  operation  was
erformed  with  the  help  of  Ligasure  Precise®.  Finally,  the
aemostasis  of  the  thyroid  cell  and  laterocervical  spaces  was
hecked.
A  Redon  No.8  type  suction  drain  was  placed  in  all  cases
n  the  corresponding  laterocervical  vascular  space.  Then
--4  ml  of  Tissucol® (Baxter,  Hyland  Inmuno)  ﬁbrin  glue
ere  applied  without  spraying  over  the  surgical  bed  in  the
ase  group  (Fig.  3)  (Baxter,  Hyland  Inmuno  (Baxter,  Hyland
nmuno.  Reg.  No.  Reg.:  60426  and  60427)  of  the  Spanish
edicines  Agency  Kit  used  for  wounds  in  general).
In  the  post-operative  period,  following  the  protocol
stablished  in  our  unit,  the  criteria  to  remove  the  drain
as  when  the  debit  was  ≤  20  ml/24  h  and  serous  in  appear-
nce,  for  both  the  case  group  and  the  control  group,  and
hen  the  patient  was  taking  a  normal  diet.  All  the  patients
ere  discharged  from  hospital  after  the  surgical  drain  was
emoved.
tatistical  analysis
irst  a  data  validation,  an  analysis  of  consistency  and  of
issing  values  or  possible  erroneous  data  was  performed.
A  variance  analysis  test  (ANOVA)  was  performed  in  order
o  analyse  the  continuous  variables  or  a  non-parametric  test
Wilcoxon)  if  the  criteria  for  applying  the  ANOVA  test  were
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Skin
RFigure  1  
not  met.  A  chi-squared  test  was  used  to  analyse  the  categor-
ical  variables  or  Fisher’s  exact  test  if  the  criteria  for  applying
the  Chi-square  test  were  not  met.  The  T-test  was  used  to
compare  means  for  2  related  samples.  SPSS  20.0  software
was  used  for  the  statistical  analysis.  The  statistical  analysis
was  performed  with  a  95%  conﬁdence  level.
Figure  2  Functional  laterocervical  lymph  node  emptying.
A
t
c
w incision.
esults total  of  60  patients  were  included.  We  performed  30
hyroidectomies  +  central  emptying  +  unilateral  laterocervi-
al  emptying,  applying  Tissucol® ﬁbrin  glue  (case  group)  and
e  compared  them  with  30  patients  where  Tissucol® ﬁbrin
Figure  3  Placing  the  Tissucol® ﬁbrin  glue.
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Table  1  Comparison  of  the  clinicopathological  variables  between  the  groups.
Variables  Surgical  techniques  p
Case  group:  application  of  Tissucol® Control  group
Patients,  n  30  30
Male/female,  n  5/25  9/21  NS
Age, years,  mean  ±  SD  52  ±  8  50  ±  7  NS
BMI, mean  ±  SD  23  ±  2  26  ±  3  NS
Duration of  the  operation,  min,  mean  ±  SD  90  ±  8  100  ±  12  NS
Length of  incision,  cm,  mean  ±  SD 6  ±  1 6  ±  1 NS
Hospital stay,  days,  mean  ±  SD 2  ±  0.5 6  ±  2 <  0.05
Total drainage  debit,  ml,  median  (range) 51  (29--72) 110  (74--132) <  0.05
Removal of  drain,  hours,  median  (range)  36  (24--48)  120  (96--168)  <  0.01
Haematoma,  n  (%)  None  None  NS
Seroma, n  (%)  2  (6.6%)  3  (10%)  NS
Postoperative  pain,  VAS,  median  (range) 2  (2--4) 3  (2--4)  NS
Transient hypocalcaemia,  n  (%) 9  (30%) 7  (23%) NS
Transient dysphonia,  n  (%) 3  (10%) 3  (10%) NS
Pathological  anatomy  (papillary  carcinoma) 30  30  NS
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acm: centimetres; SD: standard deviation; VAS: visual analogue sca
lue  was  not  applied  (control  group).  The  intervention  was
uccessfully  completed  in  all  patients.  They  were  all  classi-
ed  as  ASA  I--II.
Most  of  the  patients  were  female  (46  women,  14  men).
he  mean  age  of  the  series  was  50  ±  8.  No  statistically  signif-
cant  differences  were  observed  between  the  study  groups.
he  mean  surgery  time  of  the  total  thyroidectomy  +  central
ymph  node  emptying  +  unilateral  lateral  lymph  node  empty-
ng  was  slightly  less  in  the  case  group,  without  the  difference
eing  statistically  signiﬁcant  (Table  1).  No  intraoperative
omplications  were  detected.
With  regard  to  the  days  of  hospitalisation,  the  mean
tay  was  2  ±  0.5  days  for  the  case  group  and  6±2  days  for
he  control  group,  with  a  p  <  0.05.  As  we  mentioned  ear-
ier,  following  our  postoperative  protocol,  all  the  patients
ere  discharged  after  their  surgical  drain  had  been  removed
when  the  debit  was  ≤  20  ml/24  h  and  serous  in  appearance,
oth  for  the  case  group  and  the  control  group).  The  median
f  the  total  quantity  of  drainage  debit  was  signiﬁcantly
igher  for  the  control  group.  The  median  time  that  the
rain  was  removed  was  36  h  after  surgery  for  the  group  with
issucol® and  120  h  for  the  group  without  Tissucol® (Table  1).
We  found  5 seromas:  2  in  the  case  group  and  3  in  the
ontrol  group.  Dysphonia  presented  in  6  patients,  at  their
ollow-up,  transient  in  all  cases.  The  onset  of  postoperative
ysphonia  was  diagnosed  through  the  clinical  symptoms;  we
o  not  perform  systematic  laryngoscopies  on  our  patients
Table  1).
If we  consider  that  the  daily  cost  of  hospitalisation  for  one
atient  after  thyroidectomy  is  188.86D  in  our  institution,
he  resulting  average  cost  per  patient  for  the  case  group
as  377.72D  .  By  contrast,  it  was  signiﬁcantly  higher  for  the
ontrol  group:  1133.16D  (p  <  0.05).iscussion
ew  adhesives  and  sealants  have  appeared  in  recent
ears,17--28 such  as  Tissucol®,  widely  used  in  many  ﬁelds
c
r
tMI: body mass index; min: minutes; ml: millilitres; n: number.
f  surgery  in  order  to  achieve  complete  haemostasis,  and
hich  when  applied  in  the  thyroid  space  can  reduce  local
omplications  after  thyroidectomy  and  hemithyroidectomy.
his  ﬁbrin  glue  comprises  2  components  of  human  origin:
reeze-dried  adhesive  protein  concentrate  to  be  dissolved
ith  aprotinin  solution,  and  freeze-dried  thrombin.
When  these  substances  are  combined,  immediately
efore  application,  they  form  ﬁbrin.  The  ﬁbrin  produced
dheres  to  the  tissues  that  are  exposed  by  the  surgical  inter-
ention,  forming  a  mesh  which  serves  as  a  support  for  the
roliferation  of  ﬁbroblasts  and  capillaries  which  proliferate
uring  the  healing  process.  In  the  ﬁnal  healing  process  of  the
ound,  the  solidiﬁed  ﬁbrin  glue  is  completely  reabsorbed
ver  a period  of  6--8  weeks.
The  application  of  Tissucol® is  indicated  in  the  treat-
ent  of  oozing,  sealing  and/or  adhesion  of  tissue  in
urgical  interventions,  enabling  reduced  bleeding  and
ymphorragia.17,23,24 In  our  case  we  used  Tissucol® for  its
dhesive  properties,  rather  than  its  haemostatic  properties,
n  order  to  reduce  lymphorrhagia  in  the  virtual  space  created
y  dissection  and  lymphadenectomy.
Despite  the  fact  that  placing  drains  in  neck  surgery  has
lways  been  controversial,  our  group  advocates  their  sys-
ematic  use  after  total  thyroidectomy  +  central  lymph  node
mptying  +  lateral  emptying.7,13,14,16 As  we  explained  in  pre-
ious  paragraphs,  we  placed  a  drain  in  all  the  patients,  and
his  was  removed  before  discharge  from  hospital  when  it
ad  fulﬁlled  the  aforementioned  criteria  (debit  <  20  ml/24  h,
erous  in  appearance,  after  starting  a  normal  diet).
Bearing  in  mind  that  both  the  case  group  and  the  con-
rol  group  were  homogeneous  with  regard  to  age,  sex  and
MI,  we  found  no  statistically  signiﬁcant  differences  in  terms
f  the  variables  studied:  surgery  time,  length  of  incision,
natomopathological  type  of  the  tumour,  intraoperative
omplications,  postoperative  complications,  hypoparathy-
oidism  and  recurrent  transient  paralysis.
Our  study  shows  that  in  the  group  of  patients  in  whom
he  Tissucol® ﬁbrin  glue  was  used,  the  mean  stay  was  2  ±  0.5
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days,  compared  to  6  ±  2  days  for  the  control  group  (p  <  0.05).
We  put  this  reduction  in  the  patients’  hospital  stay  down
to  the  reduced  drainage  debit  which  enabled  the  drain  to
be  removed  early:  a  mean  of  1.5  days  after  surgery  in  the
Tissucol®,  group  compared  to  a  mean  of  5  days  in  the  control
group.  However,  in  our  case  this  was  not  accompanied  by  the
consequent  reduced  risk  of  infection  and  pain,  which  has
been  reported  in  other  published  series.16 In  other  words,
the  application  of  ﬁbrin  glue  did  not  reduce  the  rate  of
complications,  but  it  did  reduce  the  number  of  days  of
drainage,  achieving  an  earlier  debit  of  ≤  20  ml/24  h.
It  is  important  that  the  patients’  shortened  hospital  stay
results  in  a  signiﬁcant  reduction  of  hospital  costs  which
implies  a  signiﬁcant  ﬁnancial  saving.  As  we  mentioned,  the
mean  daily  stay  for  these  types  of  patients  is  188.86D in  our
hospital,  which  means  that  the  average  cost  per  patient  for
the  case  group  was  signiﬁcantly  less  compared  to  the  control
group  (377.72D  vs.  1133.16D  ),  with  p  <  0.05.
We  can  conclude  therefore  that  in  our  environment  the
application  of  Tissucol® ﬁbrin  glue  statistically  signiﬁcantly
reduced  the  hospital  stay  of  the  operated  patients,  with-
out  affecting  the  onset  of  complications  associated  with  the
intervention  and  with  the  consequent  ﬁnancial  saving  for  the
institution.
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